Hemangioma, Kaposiform Hemangioendothelioma
Conditions
Keywords
Kaposiform Hemangioendothelioma, Kasabach-Merritt Syndrome, Sirolimus, Rapamycin
Brief summary
to evaluate the safety and efficacy of Low-dose sirolimus in Kaposiform Hemangioendothelioma in Chinese children by a prospective, randomized open trial.
Detailed description
The clinically commonly used dose of sirolimus for Kaposiform Hemangioendothelioma is 0.8 mg/m2 administered twice daily, and the blood concentration can be maintained at 10-15 ng/ml according to the pharmacokinetic formula.Related research reports that maintaining low blood concentration of sirolimus is effective in the treatment of certain vascular malformations and hemangioma, and complications are less. In the clinical practice, we found that the blood concentration was maintained at 7-10 ng/ml, and the patients still achieved good results and the chance of infections decreased. Therefore, this clinical trial was designed.In this trial, two different dosing regimens with corresponding blood concentration were designed to compare the safety and efficacy.In the high concentration group, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL(excluding 10 ng/ml), and it is still used at 0.8 mg/m2 administered twice daily.The low concentration group is 7-10 ng/ml (including 10 ng/ml), and the initial use of sirolimus is 0.7mg/m2 administered twice daily.The dose was adjusted according to the formula after two weeks.The follow-up and evaluation were performed according to a strictly established follow-up schedule after taking the drug.
Interventions
DRUGSirolimus(0.8mg/m2)
The initial use of sirolimus is 0.8mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
DRUGSirolimus(0.7mg/m2)
The initial use of sirolimus is 0.7mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
Sponsors
Children's Hospital of Fudan University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 12 Years
Healthy volunteers
No
Inclusion criteria
* Kaposiform Hemangioendotheliomas with or without Kasabach-Merritt Phenomenon. * 0 - 12 years of age at the time of study entry. * Male or female. * Consent of parents (or the person having parental authority in families): Signed and dated written informed consent.
Exclusion criteria
* with hematological diseases. * with other solid tumors. * with hypertension, diabetes, adrenal insufficiency, neurological diseases, liver and kidney dysfunction, and cardiopulmonary insufficiency. * with tuberculosis,cytomegalovirus and Epstein-Barr virus infection before the treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| response to treatment | 1 year after taking the drug | it is a variable outcome, including complete responses, partial response and no response. The definitions are : Complete Response： 1. platelets counts is greater than 100×10\^9/L. 2. significant volume reduction is greater than 80%. 3. Fibrinogen levels at 2-4g/L. 4. The surface skin of the tumor is lighter or the tumor is softer significantly. Partial Response: 1. platelets counts is greater than 40×10\^9/L. 2. significant volume reduction is greater than 50%. 3. Fibrinogen levels at less than 50% reduction from baseline. 4. The surface skin of the tumor and palpation of the tumor have no change or less change. No Response: 1. platelets counts is less than 40×10\^9/L. 2. significant volume reduction is less than 50% or the tumor is bigger. 3. Fibrinogen levels at grater then 50% reduction from baseline. 4. The surface skin of the tumor is darker or the tumor is harder. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | 1 year after taking the drug | Monitoring patient's clinical biochemical indicators and symptoms |
Countries
China
Outcome results
None listed